Serbousek Jon Carl 4
4 · Orthofix Medical Inc. · Filed Jan 9, 2023
Insider Transaction Report
Form 4
Serbousek Jon Carl
President of Global Spine
Transactions
- Award
Common Stock
2023-01-05+40,764→ 276,143 total - Award
Common Stock
2023-01-05+81,967→ 358,110 total - Award
Common Stock
2023-01-05+45,872→ 235,379 total
Footnotes (4)
- [F1]Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.
- [F2]Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.
- [F3]Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.
- [F4]Includes 307,621 unvested restricted stock units.